Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleCLINICAL INVESTIGATIONS

In Vivo Imaging of Macrophage Activity in the Coronary Arteries Using 68Ga-DOTATATE PET/CT: Correlation with Coronary Calcium Burden and Risk Factors

Axel Rominger, Tobias Saam, Eva Vogl, Christopher Übleis, Christian la Fougère, Stefan Förster, Alexander Haug, Paul Cumming, Maximilian F. Reiser, Konstantin Nikolaou, Peter Bartenstein and Marcus Hacker
Journal of Nuclear Medicine February 2010, 51 (2) 193-197; DOI: https://doi.org/10.2967/jnumed.109.070672
Axel Rominger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tobias Saam
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eva Vogl
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher Übleis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian la Fougère
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefan Förster
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander Haug
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Cumming
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maximilian F. Reiser
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Konstantin Nikolaou
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Bartenstein
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcus Hacker
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

We measured the uptake of the somatostatin receptor ligand 68Ga-[1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″-tetraacetic acid]-d-Phe1,Tyr3-octreotate (DOTATATE) in the left anterior descending coronary artery (LAD) in association with calcified plaques (CPs) and cardiovascular risk factors. Methods: Seventy consecutive tumor patients were examined by whole-body 68Ga-DOTATATE contrast-enhanced PET/CT. Blood-pool–corrected standardized uptake value (target-to-background ratio) was measured in the LAD, and CT images were used to detect CP. Cardiovascular risk factors and history of prior cardiovascular events were recorded. Results: 68Ga-DOTATATE uptake was detectable in the LAD of all patients. Target-to-background ratio in the LAD correlated significantly with the presence of CP (R = 0.34; P < 0.01), prior vascular events (R = 0.26; P < 0.05), and male sex (R = 0.29; P < 0.05), whereas CP correlated with these parameters but also with age (R = 0.34; P < 0.01) and hypertension (R = 0.25; P < 0.05). Conclusion: In a series of oncologic patients, those with prior cardiovascular events and calcified atherosclerotic plaques showed significantly increased 68Ga-DOTATATE uptake in the LAD, suggesting a potential role of this tracer for plaque imaging in the coronary arteries.

  • atherosclerosis
  • plaque imaging
  • 68Ga-DOTATATE PET/CT
  • cardiovascular
  • coronary arteries

Atherosclerosis is one of the leading causes of morbidity and mortality in the world (1), accounting for most myocardial infarctions and sudden cardiac deaths (2). New imaging methods can help identify high-risk patients who bear vascular lesions that are vulnerable to thrombosis, the so-called vulnerable plaques. Active inflammation is implicated in initiation, progression, and disruption of vulnerable plaques and consequently represents an emerging target for the imaging and treatment of atherosclerosis. Local inflammatory processes can now be assessed by noninvasive imaging methods intended to identify the vulnerable plaque on the basis of its physiologic properties (3,4).

Whole-body 18F-FDG PET/CT is a reliable and well-established method to image and quantify plaque inflammation (5). There was good correlation between carotid plaque 18F-FDG uptake in vivo and macrophage staining from the corresponding histologic sections (6). Furthermore, there was a weak but highly significant correlation between 18F-FDG uptake and cardiovascular risk factors (7) and the occurrence of future cardiovascular events (8). However, most of this work has been performed on relatively large arteries, such as the aorta or the carotid arteries. Although pathologic features in these arteries are likely representative of a general atherosclerotic disease, it is the thromboembolic complications arising in the coronary arteries that are responsible for most deaths (9). Furthermore, most of these fatal cardiovascular events occur in coronary arteries with less than 50% stenosis (10), indicating that information about luminal stenosis is insufficient to predict the vulnerability of a plaque. Although 18F-FDG can serve as a metabolic marker for inflamed plaques in the coronary arteries, its applicability is limited by poor control of physiologic uptake of 18F-FDG in the myocardium, which frequently obscures the vascular pathology (11).

As an alternative to the visualization of macrophages with 18F-FDG PET, somatostatin receptors of subtype 2 (SSTR2), which are expressed by macrophages (12), can be detected with the PET ligand 68Ga-[1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″-tetraacetic acid]-d-Phe1,Tyr3-octreotate (DOTATATE) (13). Unlike the case of 18F-FDG, there is no physiologic 68Ga-DOTATATE uptake in the myocardium, which permits more clear and consistent detection of macrophage accumulation in the coronary arteries.

The purpose of the present study was to correlate 68Ga-DOTATATE uptake in the left anterior descending coronary artery (LAD) with the presence of calcified plaques (CPs) and cardiovascular risk factors. To this end, we retrospectively reanalyzed 68Ga-DOTATATE scans that had been obtained for the investigation of neuroendocrine tumors.

MATERIAL AND METHODS

Patients

The study group consisted of 70 consecutive patients who had been referred to our institution for a contrast-enhanced PET/CT scan because of the presence of a neuroendocrine tumor. The study protocol was approved by the local clinical institutional review board and complied with the Declaration of Helsinki. None of the patients was under current steroid medication or other treatments known to affect vessel wall metabolism. Age, body mass index (BMI), and common cardiovascular risk factors such as hypertension, hypercholesterolemia, smoking habits, family history, prior vascular events defined as myocardial infarction, revascularization procedures or stroke, and diabetes mellitus were documented from charts.

Imaging Technique

All patients underwent 68Ga-DOTATATE PET/CT on a Gemini scanner (Philips), consisting of a germanium oxyorthosilicate full-ring PET scanner and a 2-detector-row CT scanner. Patients received 20 mg of furosemide at the same time as an intravenous injection of 3 MBq of 68Ga-DOTATATE (mean dose, 211 MBq) per kilogram. Sixty minutes after radiotracer administration, transmission data were acquired using a whole-body low-dose CT scan with conventional parameters. Next, a contrast-enhanced CT scan (Ultravist 370, 370 mg of iodine/mL; Bayer-Schering AG) with a slice thickness of 3 mm (195 mAs, 120 kV, 512 × 512 matrix, 5 mm/s increment, 0.5-s rotation time, and 1.5 pitch index) was obtained. Finally, caudocephalad PET emission recordings were acquired in 3-dimensional mode with a 144 × 144 matrix. After scatter and decay correction, PET data were reconstructed iteratively with and without attenuation correction and then reoriented in axial, sagittal, and coronal slices. A fully 3-dimensional reconstruction algorithm based on the row-action maximum-likelihood algorithm was applied with the PET-View software (Philips).

Image Analysis

68Ga-DOTATATE Uptake

PET/CT scans were examined by an experienced reader who was unaware of patient and clinical information. Maximal standardized uptake values (SUVs) were measured from the left sinus of Valsalva to the outlet of the first diagonal branch of the LAD, which we herein define as LAD. We manually placed regions of interest (ROIs) of fixed size in all patients. The size was chosen to match the lumen of the vessel. Finally, the correct placement of the ROI within the lumen of the coronary artery was in each case visually verified by inspection in all 3 planes, using the zoom display tool and moving the ROIs along the long axis to find the regions of maximal SUV (Fig. 1).

FIGURE 1. 
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1. 

PET/CT image analysis. Example of SUV measurement in LAD. PET/CT images of 64-y-old woman with history of smoking (40 pack-years), diabetes, and hypercholesterolemia. From left to right: first panel shows coronal slice of PET scan. Red line indicates same axial slice as that presented in other 3 images. Second panel shows axial CT image of coronary artery, which was used to localize LAD. Red circle in panels 2, 3, and 4 indicates ROI, placed in LAD. Third panel shows axial PET slice, and fourth panel shows fused CT and PET image. SUV was measured on fused PET/CT images along course of vessel. Maximum SUV in this patient was 0.9, and mean venous SUV in upper and lower vena cava was 0.5, resulting in target–to–background ratio (TBR) of 1.8.

Blood-pool SUV was the mean from 3 ROIs placed in the mid lumen of the vena cava inferior and the vena cava superior. The maximal SUV of the LAD was divided by blood-pool SUV, yielding a target-to-background ratio (TBR).

In addition, the major aortic divisions (ascending, arch, descending, abdominal) and the iliac and common carotid arteries were analyzed for the presence of 68Ga-DOTATATE uptake. We placed simple circular ROIs on the coregistered PET/CT slices, as described previously (8).

Plaque Burden

The CT scans were examined for the presence of CPs in the wall of the LAD (vascular attenuation > 130 Hounsfield units) (14). Patients were divided into those with CP and those without discernible CP. Soft plaques were not discernible in the LAD. The major peripheral arteries listed above were also scanned for presence of calcifications.

Reproducibility

To assess intra- and interreader reproducibility, TBR and CP measurements were repeated 8 wk after the initial review by the same reviewer and by a second reviewer, for the calculation of intraclass correlation coefficients (ICCs) with 95% confidence intervals (CIs).

Statistical Analysis

Categoric variables are presented with absolute and relative frequencies, whereas continuous variables are presented as mean and SD. For between-group comparisons for the TBR, unpaired Student t tests were used for parametric data, and Mann–Whitney U rank sum tests were used for nonparametric data. The Pearson correlation coefficient was used to correlate TBR with CP and with age, BMI, and the occurrence of cardiovascular risk factors. To identify the optimal TBR threshold value, receiver-operating-characteristic analysis was performed (15).

RESULTS

Patient Population

68Ga-DOTATATE uptake measurements in the LAD were feasible in all patients. Relevant patients' baseline characteristics are reported in Table 1.

View this table:
  • View inline
  • View popup
TABLE 1

Baseline Characteristics of Study Population (n = 70)

Correlation of Baseline Parameters

Table 2 shows the correlations of baseline characteristics with TBR and CP in the LAD. Within the 70 patients, significant correlations were observed between TBR and male sex (R = 0.29; P < 0.05) and prior vascular events (R = 0.26; P < 0.05). Furthermore, there was a significant correlation between the presence of TBR and CP (R = 0.34; P < 0.01; Fig. 2). In 14 of 25 (56%) cases, the uptake was not colocalized in the CP.

View this table:
  • View inline
  • View popup
TABLE 2

Correlation of Baseline Characteristics with TBR in LAD and CP in LAD

FIGURE 2. 
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2. 

Relation of TBR to calcification. Scatter plot shows individual ratios for all patients, separated into those with CP (CP (+)) and those without CP (CP (−)). Mean values are indicated with horizontal line.

CP correlated significantly with age (R = 0.34; P < 0.01), male sex (R = 0.39; P < 0.01), hypertension (R = 0.25; P < 0.05), and prior vascular events (R = 0.37; P < 0.01).

Images from patients with high TBR are clearly distinct from low-TBR images (Fig. 3). Receiver-operating-characteristic analysis indicated that a cutoff TBR greater than or equal to 1.5 gave an optimal threshold for specifically distinguishing between patients with and without coronary calcifications. Of the 12 high-uptake patients, 75% also had CPs within the LAD, versus only 28% of the low-uptake patients.

FIGURE 3. 
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 3. 

Proportion of 68Ga-DOTATATE uptake and calcifications in LAD. Patients with high DOTATATE uptake (TBR ≥ 1.5) also show high percentage of CPs within LAD (left diagram), whereas patients with low DOTATATE uptake (TBR < 1.5) had low percentage of CPs within LAD (right diagram).

There was a significant correlation between TBR and presence of CP in the abdominal aorta (R = 0.256; P < 0.05), the right iliac artery (R = 0.273; P < 0.05), and both common carotid arteries (right, R = 0.358; P < 0.01; left, R = 0.297; P < 0.05). Furthermore, there were significant correlations (P < 0.05) between TBR and male sex and also prior cardio- or cerebrovascular events in the common carotid arteries.

Patients undergoing statin or Sandostatin (Novartis Pharma AG) therapy, compared with the other patients, did not show significantly altered 68Ga-DOTATATE uptake.

Reproducibility

The intrareader ICC for TBR measurements was 0.97 (95% CI, 0.93–0.99), and the interreader ICC was 0.94 (95% CI, 0.89–0.97).

DISCUSSION

We present the first quantitation of 68Ga-DOTATATE uptake in the anterior descending coronary artery using PET/CT. We found a significant correlation between 68Ga-DOTATATE uptake and the presence of vessel wall calcifications. On stratifying the subjects into groups with high and low tracer uptake, we found that most of the patients with high tracer uptake also had calcifications (seen in only a third of the patients with low 68Ga-DOTATATE uptake) in the LAD. Our finding of 44% colocalization is in line with previous studies conducted with 18F-FDG, reviewed by Kato et al. (16). Furthermore, patients with prior cardiovascular events had significantly increased 68Ga-DOTATATE uptake in the LAD, suggesting this radiotracer as a potential biomarker for the identification of vulnerable coronary artery plaques and indeed in other major vessels, as already shown for 18F-FDG.

Molecular Background

Several publications have demonstrated the expression of somatostatin subtype 1 receptors and SSTR2 on human macrophages (12,17). 68Ga-DOTATATE, which has hitherto been used for the assessment of neuroendocrine tumors, has a high affinity and selectivity for SSTR2 and is rapidly cleared from nontarget tissues, thus offering good target-to-nontarget imaging properties (13). Indeed, the myocardium was devoid of significant 68Ga-DOTATATE uptake, which is an important precondition for using this tracer for the assessment of atherosclerosis in the coronary arteries.

Comparison to Other Biomarkers of Atherosclerosis

Several previous studies reported significant correlations between the presence of cardiovascular risk factors and 18F-FDG uptake in large arteries (7,18,19). Moreover, increased 18F-FDG uptake in large arteries was recently demonstrated in oncologic patients with prior cardiovascular events (19) and in oncologic patients who had a cerebro- or cardiovascular event during follow-up (8). This increased 18F-FDG uptake is presumably an indicator of elevated metabolic activity in macrophages resident in the inflamed plaques. Macrophage proliferation has been documented in culprit lesions after plaque ruptures, leading to myocardial infarction or sudden cardiac death (9). In the only previous 18F-FDG PET study of the coronary arteries, a series of 32 patients was investigated according to oncologic indications (11); of the 17 patients in whom arterial wall 18F-FDG uptake was discernible, 15 proved to have stenoses of more than 50% on coronary angiography. Nonetheless, general application of the approach is hampered by the occurrence of significant 18F-FDG uptake in the myocardium of nearly one half of the patients, despite prescan fasting or the use of a low-carbohydrate, high-fat diet. Thus, the low myocardial uptake of 68Ga-DOTATATE presents an advantage over 18F-FDG for the detection of macrophage infiltration of coronary vessels; we could evaluate 68Ga-DOTATATE uptake in the LAD in all 70 of our patients, with excellent intra- and interreader reproducibility for the TBR values, comparable to those obtained earlier for 18F-FDG uptake measurements in peripheral vessels (20).

Future PET/CT studies using dedicated CT and electrocardiogram-gated PET should enable the measurement of 68Ga-DOTATATE uptake in the whole coronary artery tree while also obtaining CT calcium scores. In the present cross-sectional study, the magnitude of CP in the LAD of oncology patients correlated with most cardiovascular risk factors, underlining the inherent association of CPs with the presence of atherosclerosis (21). Macrophages have been targeted as a marker of plaque vulnerability in imaging studies with several radiopharmaceuticals other than 18F-FDG. Kietselaer et al. investigated 4 preoperative carotid endarterectomy patients with 99mTc-annexin A5, a labeled plasma protein that binds to cell membranes of apoptotic macrophages (22); increased radiotracer uptake was observed in patients with a recent prior cardiovascular event who also showed histopathologic features of unstable plaque. Other studies have used choline derivatives, which are transported into activated macrophages and incorporated into the cell membrane; elevated uptake of these tracers is reported in the walls of vessels with and without calcifications (16).

Limitations

Because this study was performed in tumor patients, the findings may be imperfectly generalizable to investigations of vascular disease per se. Although the stringent national guidelines for recruitment of healthy control subjects (related to the radiation exposure) necessitated the use of an ill cohort, the present findings make a compelling rationale for conducting prospective PET/CT vascular examinations using 68Ga-DOTATATE in noncancer patients. Furthermore, in these patients noncardiac CT scans were obtained so that the proximal portion of the left coronary artery only could be reliably evaluated.

CONCLUSION

On the basis of in vitro findings of the expression of SSTR2 on macrophages, we measured 68Ga-DOTATATE uptake in the LAD of a series of oncologic patients. Those patients with prior cardiovascular events and calcified atherosclerotic plaques showed significantly increased 68Ga-DOTATATE uptake in the LAD, suggesting a potential role of this tracer for plaque imaging and characterization in the coronary arteries.

Acknowledgments

A substantial part of this work originated from the doctoral thesis of Eva Vogl.

Footnotes

  • COPYRIGHT © 2010 by the Society of Nuclear Medicine, Inc.

References

  1. 1.↵
    Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics: 2009 update—a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119:e21–e181.
    OpenUrlFREE Full Text
  2. 2.↵
    Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I. Circulation. 2003;108:1664–1672.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    Saam T, Hatsukami TS, Takaya N, et al. The vulnerable, or high-risk, atherosclerotic plaque: noninvasive MR imaging for characterization and assessment. Radiology. 2007;244:64–77.
    OpenUrlCrossRefPubMed
  4. 4.↵
    Langer HF, Haubner R, Pichler BJ, Gawaz M. Radionuclide imaging: a molecular key to the atherosclerotic plaque. J Am Coll Cardiol. 2008;52:1–12.
    OpenUrlCrossRefPubMed
  5. 5.↵
    Rudd JH, Myers KS, Bansilal S, et al. 18Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J Am Coll Cardiol. 2007;50:892–896.
    OpenUrlCrossRefPubMed
  6. 6.↵
    Tawakol A, Migrino RQ, Bashian GG, et al. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol. 2006;48:1818–1824.
    OpenUrlCrossRefPubMed
  7. 7.↵
    Yun M, Jang S, Cucchiara A, Newberg AB, Alavi A. 18F FDG uptake in the large arteries: a correlation study with the atherogenic risk factors. Semin Nucl Med. 2002;32:70–76.
    OpenUrlCrossRefPubMed
  8. 8.↵
    Rominger A, Saam T, Wolpers S, et al. 18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease. J Nucl Med. 2009;50:1611–1620.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    Finn AV, Nakazawa G, Narula J, Virmani R. Culprit plaque in myocardial infarction going beyond angiography. J Am Coll Cardiol. 2007;50:2204–2206.
    OpenUrlCrossRefPubMed
  10. 10.↵
    Ambrose JA, Tannenbaum MA, Alexopoulos D, et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol. 1988;12:56–62.
    OpenUrlCrossRefPubMed
  11. 11.↵
    Wykrzykowska J, Lehman S, Williams G, et al. Imaging of inflamed and vulnerable plaque in coronary arteries with 18F-FDG PET/CT in patients with suppression of myocardial uptake using a low-carbohydrate, high-fat preparation. J Nucl Med. 2009;50:563–568.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    Armani C, Catalani E, Balbarini A, Bagnoli P, Cervia D. Expression, pharmacology, and functional role of somatostatin receptor subtypes 1 and 2 in human macrophages. J Leukoc Biol. 2007;81:845–855.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    Breeman WA, de Jong M, de Blois E, Bernard BF, Konijnenberg M, Krenning EP. Radiolabelling DOTA-peptides with 68Ga. Eur J Nucl Med Mol Imaging. 2005;32:478–485.
    OpenUrlCrossRefPubMed
  14. 14.↵
    Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990;15:827–832.
    OpenUrlCrossRefPubMed
  15. 15.↵
    Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148:839–843.
    OpenUrlPubMed
  16. 16.↵
    Kato K, Schober O, Ikeda M, et al. Evaluation and comparison of 11C-choline uptake and calcification in aortic and common carotid arterial walls with combined PET/CT. Eur J Nucl Med Mol Imaging. 2009;36:1622–1628.
    OpenUrlCrossRefPubMed
  17. 17.↵
    Elliott DE, Li J, Blum AM, Metwali A, Patel YC, Weinstock JV. SSTR2A is the dominant somatostatin receptor subtype expressed by inflammatory cells, is widely expressed and directly regulates T cell IFN-gamma release. Eur J Immunol. 1999;29:2454–2463.
    OpenUrlCrossRefPubMed
  18. 18.↵
    Ben-Haim S, Kupzov E, Tamir A, Israel O. Evaluation of 18F-FDG uptake and arterial wall calcifications using 18F-FDG PET/CT. J Nucl Med. 2004;45:1816–1821.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    Paulmier B, Duet M, Khayat R, et al. Arterial wall uptake of fluorodeoxyglucose on PET imaging in stable cancer disease patients indicates higher risk for cardiovascular events. J Nucl Cardiol. 2008;15:209–217.
    OpenUrlCrossRefPubMed
  20. 20.↵
    Rudd JH, Myers KS, Bansilal S, et al. Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J Nucl Med. 2008;49:871–878.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    Budoff MJ, Shaw LJ, Liu ST, et al. Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients. J Am Coll Cardiol. 2007;49:1860–1870.
    OpenUrlCrossRefPubMed
  22. 22.↵
    Kietselaer BL, Reutelingsperger CP, Heidendal GA, et al. Noninvasive detection of plaque instability with use of radiolabeled annexin A5 in patients with carotid-artery atherosclerosis. N Engl J Med. 2004;350:1472–1473.
    OpenUrlCrossRefPubMed
  • Received for publication September 11, 2009.
  • Accepted for publication November 9, 2009.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 51 (2)
Journal of Nuclear Medicine
Vol. 51, Issue 2
February 2010
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
In Vivo Imaging of Macrophage Activity in the Coronary Arteries Using 68Ga-DOTATATE PET/CT: Correlation with Coronary Calcium Burden and Risk Factors
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
In Vivo Imaging of Macrophage Activity in the Coronary Arteries Using 68Ga-DOTATATE PET/CT: Correlation with Coronary Calcium Burden and Risk Factors
Axel Rominger, Tobias Saam, Eva Vogl, Christopher Übleis, Christian la Fougère, Stefan Förster, Alexander Haug, Paul Cumming, Maximilian F. Reiser, Konstantin Nikolaou, Peter Bartenstein, Marcus Hacker
Journal of Nuclear Medicine Feb 2010, 51 (2) 193-197; DOI: 10.2967/jnumed.109.070672

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
In Vivo Imaging of Macrophage Activity in the Coronary Arteries Using 68Ga-DOTATATE PET/CT: Correlation with Coronary Calcium Burden and Risk Factors
Axel Rominger, Tobias Saam, Eva Vogl, Christopher Übleis, Christian la Fougère, Stefan Förster, Alexander Haug, Paul Cumming, Maximilian F. Reiser, Konstantin Nikolaou, Peter Bartenstein, Marcus Hacker
Journal of Nuclear Medicine Feb 2010, 51 (2) 193-197; DOI: 10.2967/jnumed.109.070672
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIAL AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Factors Associated with Myocardial Uptake on Oncologic Somatostatin PET Investigations and Differentiation from Myocardial Uptake of Acute Myocarditis
  • Flexible 3-D Electrochemical Impedance Spectroscopy Sensors Incorporating Phase Delay for Comprehensive Characterization of Atherosclerosis
  • Imaging Cardiovascular Calcification
  • PET/CT Imaging of Unstable Carotid Plaque with 68Ga-Labeled Somatostatin Receptor Ligand
  • Early Detection and Treatment of the Vulnerable Coronary Plaque: Can We Prevent Acute Coronary Syndromes?
  • Detection of Atherosclerotic Inflammation by 68Ga-DOTATATE PET Compared to [18F]FDG PET Imaging
  • Imaging Vulnerable Plaque: A Medical Necessity or a Scientific Curiosity?
  • Noninvasive Molecular Imaging of Disease Activity in Atherosclerosis
  • The Future of Cardiovascular Imaging
  • 64Cu-DOTATATE for Noninvasive Assessment of Atherosclerosis in Large Arteries and Its Correlation with Risk Factors: Head-to-Head Comparison with 68Ga-DOTATOC in 60 Patients
  • 64Cu-DOTATATE PET/MRI for Detection of Activated Macrophages in Carotid Atherosclerotic Plaques: Studies in Patients Undergoing Endarterectomy
  • Targeting P-Selectin by Gallium-68-Labeled Fucoidan Positron Emission Tomography for Noninvasive Characterization of Vulnerable Plaques: Correlation With In Vivo 17.6T MRI
  • Peptide Receptor-Targeted Radionuclide Therapy Alters Inflammation in Atherosclerotic Plaques
  • The Role of 68Ga-DOTATATE PET/CT in Suspected Neuroendocrine Tumors
  • Detection of High-Risk Atherosclerotic Plaque: Report of the NHLBI Working Group on Current Status and Future Directions
  • Correlation of Inflammation Assessed by 18F-FDG PET, Active Mineral Deposition Assessed by 18F-Fluoride PET, and Vascular Calcification in Atherosclerotic Plaque: A Dual-Tracer PET/CT Study
  • Google Scholar

More in this TOC Section

  • Feasibility of Ultra-Low-Activity 18F-FDG PET/CT Imaging Using a Long–Axial-Field-of-View PET/CT System
  • Cardiac Presynaptic Sympathetic Nervous Function Evaluated by Cardiac PET in Patients with Chronotropic Incompetence Without Heart Failure
  • Validation and Evaluation of a Vendor-Provided Head Motion Correction Algorithm on the uMI Panorama PET/CT System
Show more Clinical Investigations

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire